Can you summarize the key features of the LEADER trial, including the primary MACE end points and the patient populations studied?

Can you summarize the key features of the LEADER trial, including the primary MACE end points and the patient populations studied?

Can you summarize the key features of the LEADER trial, including the primary MACE end points and the patient populations studied?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario